How much has Twist Bioscience raised?
Twist Bioscience is a public company (Nasdaq: TWST), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- Nasdaq: TWST
- First raised
- 2013
- Notable backer
- Public shareholders
Twist Bioscience's funding rounds
Twist Bioscience's capital path moved from founding and growth capital into public-company financing.
- 2013FoundedTwist is founded to commercialize silicon-based synthetic DNA manufacturing.
- 2018IPOTwist lists on Nasdaq under TWST.
- 2021Biopharma expansionAntibody and protein-solutions offerings broaden the platform.
- 2025Fiscal 2025 annual reportTwist files its 2025 annual report and continues revenue growth.
- 2026Q2 fiscal 2026Twist reports $110.7M of fiscal second-quarter revenue and raises guidance.
Sources:Twist fiscal Q2 2026 resultsTwist fiscal Q1 2026 results
How much has Twist Bioscience raised in total?
Twist Bioscience is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are Twist Bioscience's investors?
The relevant investor base is the public shareholder base behind Nasdaq: TWST. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. Twist Bioscience's latest public materials emphasize $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is Twist Bioscience profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does Twist Bioscience's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. Twist Bioscience can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:Twist fiscal Q2 2026 resultsTwist fiscal Q1 2026 results
Twist Bioscience — frequently asked questions
